Updated News

Study: New heart failure drug cuts death by 37 percent
Catholic Online
An experimental drug, called serelaxin from the Novartis AG drug group to treat hospitalized acute heart failure patients has reported remarkable success. The death rate was decreased by as much as 37 percent compared with a placebo and appeared to be ...
Acute Heart Failure: Serelaxin Shines in Phase III TrialClinical Endocrinology News Digital Network
Novartis' heart failure drug faces hurdles despite upbeat PhIII resultsFierceBiotech
Serelaxin: Acute Heart Failure Drug Reduces Deaths By 37%, Study ShowsHuffington Post
Health.com -Forbes
all 70 news articles »